Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service? Thank you for choosing ACROBiosystems. Would you rate our product and service?
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
Rituximab biosimilar is a chimeric monoclonal antibody recombinantly expressed from HEK293, which combines the variable region of a mouse monoclonal antibody with Human constant domain.
Human IgG1 | Human Kappa
Recombinant Monoclonal
Human
CD20.
Rituximab is a genetically engineered chimeric murine / human monoclonal IgG1 kappa antibody directed against the CD20 antigen.
Application | Recommended Usage |
ELISA | 0.2-39 ng/mL |
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Protein A purified/ Protein G purified
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Rituximab biosimilar on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
The purity of Rituximab biosimilar (Cat. No. CD0-M36) is more than 95% and the molecular weight of this protein is around 135-160 kDa verified by SEC-MALS.
Immobilized Rituximab biosimilar (Cat. No. CD0-M36) at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) with a linear range of 0.2-10 ng/mL (QC tested).
ACROBiosystemsは、二重特異性抗体の治療薬への臨床開発を加速するために、高い生物活性を持つ均一なCD3δ/CD3εおよびCD3γ/CD3εタンパク質のシリーズを開発しました。
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox は、即使用可能のオルガノイド、オルガノイド分化ツールキット、創薬プロジェクトの進行を加速する、さまざまなサービスを含むオルガノイドソリューションのことです。
IL-15、IL-7、IL-21など、高品質のGMP準拠サイトカイン製品を提供しており、免疫細胞治療薬の臨床研究をサポートし、医薬品規制当局の承認を加速できます。
注目されている50以上のCAR-Tターゲットがあり、CARの発現の検出のために設計された抗原タンパク質をフローサイトメトリーで検証し、CARの発現が高い特異性で検出できます。ロット間の一貫性が保証されています。また、PE / FITC標識タンパク質を利用することで、ワンステップ染色でCARの発現を高い特異性でバックグラウンドなしに検出できます。
CD20、Claudin18.2、CD133、GPRC5D、CCR5、CCR8などの安定で高活性な全長型膜貫通タンパク質は、免疫学、ELISA、SPR、BLI、細胞実験、CAR陽性率検出に利用できます。VLP、界面活性剤、ナノディスクなどのテクニカルプラットフォームによって複数回膜貫通タンパク質の医薬品創薬を促進できます。
GMP準拠サイトカイン、高品質の細胞活性化/増幅試薬、遺伝子改変試薬/酵素、CAR検出試薬などの製品を提供し、細胞、遺伝子治療用に全体的なソリューションを提供し、創薬から臨床研究までのすべての段階をサポートします。
これまでに知られている免疫チェックポイント分子をほぼ製品化しており、様々なタグの製品群を提供できます。天然高分子の構造はMALSによって、生物活性はELISA/SPR/BLI/FACSなどによって検証済みです。またBiotin/FITCなどの標識も選択でき、抗体のハイスループットスクリーニングに利用できます。
弊社ACROBiosystemsはADC医薬品の開発のサポートに取り組み、注目されている様々なターゲットのために、異なる種類とタグの製品が開発され、高い純度と親和性が特長です。免疫、抗体スクリーン、SPR、細胞活性検査などの実験に利用できます。Protocolも無償で提供いたします。
すべての分子のFc受容体タンパク質だけでなく、一般的な変異体やビオチン標識タイプも含まれております。お客様のモノクローナル抗体の開発をサポートします。
インターロイキン、成長因子、ケモカイン、TNF など、様々なサイトカインターゲットの自然なコンフォメーションを確保するために HEK293 によって発現されます。SDS-PAGE/HPLC/SEC-MALS によって高純度は確認され、高い生物活性は ELISA/SPR/BLI によって確認されています。
AneuroはACROBiosystemsが神経科学研究のために設計した製品群のブランドです。神経科学研究を推進するための治療・診断用研究タンパク質、PFF、組み換え神経因子など、高品質の重要なタンパク質を提供しております。
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Rituximab biosimilar (Celltrion) | CT-P10 | Approved | Celltrion Inc | Truxima, Blitzima, Ritemvia, Rituzena | EU | Leukemia, Lymphocytic, Chronic, B-Cell; Granulomatosis with Polyangiitis; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Microscopic Polyangiitis | Celltrion Healthcare Hungary Kft | 2017-02-17 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Philadelphia Chromosome; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Leukemia, Myelogenous, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Blast Crisis; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Anemia; Microscopic Polyangiitis; Leukemia, Lymphoid; Granulomatosis with Polyangiitis; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase | Details |
Hyaluronidase/Rituximab | Approved | Genentech Inc | Rituxan Hycela | United States | Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular | Genentech Inc | 2017-06-22 | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Ublituximab | TG-1101; TGTX-1101; LFB-R603; TG-1303; EMAB-6; R-603 | Approved | Tg Therapeutics Inc | Utuxin, BRIUMVI | United States | Multiple Sclerosis | Tg Therapeutics Inc | 2022-12-28 | Multiple Sclerosis, Relapsing-Remitting; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis; Lymphoma, Mantle-Cell; Neuromyelitis Optica; Lymphoma, Follicular; Richter's Syndrome; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma | Details |
Rituximab Biosimilar(Shanghai Institute Of Biological Products) | SIBP-02 | Approved | Shanghai Institute Of Biological Products Co Ltd | 生利健 | Mainland China | Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular | Shanghai Institute Of Biological Products Co Ltd | 2024-03-19 | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Ibritumomab tiuxetan | IDEC-In2B8; BAY86-5128; SHL-749; IDEC-Y2B8; IDEC-129; IDEC-2B8-MX-DTPA | Approved | Biogen Inc | Zevalin, Zavalin | United States | Lymphoma, B-Cell | Spectrum Pharmaceuticals Inc | 2002-02-19 | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Zuberitamab | HS-006 | Approved | Zhejiang Hisun Pharmaceutical Co Ltd | 安瑞昔 | Mainland China | Lymphoma, Large B-Cell, Diffuse | BioRay Pharmaceutical Co Ltd | 2023-05-12 | Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Thrombocytopenia | Details |
Ofatumumab | OMB-157; HuMax-CD2; GSK-1841157; 2F2 | Approved | Genmab A/S | Arzerra, Kesimpta | United States | Leukemia, Lymphocytic, Chronic, B-Cell | Novartis Pharma Ag | 2009-10-26 | Leukemia; Multiple Sclerosis, Relapsing-Remitting; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Multiple Sclerosis; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus | Details |
Rituximab biosimilar (Innovent Biologics) | IBI-301 | Approved | Innovent Biologics(Suzhou) Co Ltd | 达伯华, HALPRYZA | Mainland China | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Innovent Biologics(Suzhou) Co Ltd | 2020-09-30 | Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell; Burkitt Lymphoma; Leukemia, B-Cell; Philadelphia Chromosome; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, B-Cell; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blast Crisis; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Anemia; Hematologic Neoplasms; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic | Details |
Rituximab biosimilar (Sandoz) | GP-2013 | Approved | Sandoz | Riximyo, Rixathon | EU | Microscopic Polyangiitis; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell; Arthritis, Rheumatoid; Granulomatosis with Polyangiitis | Sandoz Gmbh | 2017-06-15 | Granulomatosis with Polyangiitis; Lymphoma, B-Cell; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab biosimilar (AryoGen Biopharma) | Approved | Aryogen Biopharma | Zytux | Iran | Leukemia, Myelogenous, Chronic; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Granulomatosis with Polyangiitis; Microscopic Polyangiitis | Aryogen Biopharma | 2014-01-01 | Leukemia, Myelogenous, Chronic; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details | |
Rituximab biosimilar (Biosidus) | Approved | Biosidus | Argentina | Hematologic Neoplasms | Biosidus | 2013-06-01 | Hematologic Neoplasms | Details | ||
Rituximab biosimilar (mAbxience) | RTXM-83; mAbx-02 | Approved | Mabxience Sa | Novex | Argentina | Lymphoma, Large B-Cell, Diffuse | Mabxience Sa | 2015-01-01 | Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Philadelphia Chromosome; Leukemia, Myelogenous, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Blast Crisis; Lymphoma, Large B-Cell, Diffuse; Anemia; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase | Details |
Rituximab biosimilar (Hetero Drugs) | Approved | Hetero Drugs Ltd | Maball, Mabura | India | Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Hetero Drugs Ltd | 2015-01-01 | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Rituximab biosimilar (Center of Molecular Immunology) | Approved | Center Of Molecular Immunology | CIMAbior, RituxCIM | Cuba | Lymphoma, Non-Hodgkin | null | 2017-04-01 | Lymphoma, Non-Hodgkin | Details | |
Rituximab biosimilar (Biocad) | BCD-020 | Approved | Biocad | Acellbia | Russian Federation | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin | Biocad | 2015-01-01 | Lymphoma, B-Cell, Marginal Zone; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab biosimilar (Reliance Life Sciences) | R-TPR-017 | Approved | Reliance Life Sciences | Toritz, RituxiRel | India | Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid | null | 2016-01-01 | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (CTTQ Pharma) | TQB-2303 | Approved | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Mainland China | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | 2023-05-26 | Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma, T-Cell | Details | ||
Rituximab biosimilar (Shanghai Henlius Biotech) | HLX-01 | Approved | Shanghai Henlius Biotech Inc | 汉利康 | Mainland China | Lymphoma, Non-Hodgkin | Shanghai Henlius Biopharmaceuticals Co Ltd | 2019-02-22 | Lymphoma, B-Cell; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (Amgen) | ABP-798; APB-798 | Approved | Amgen Inc | Riabni | United States | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin | Amgen Inc | 2020-12-17 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Philadelphia Chromosome; Lymphoproliferative Disorders; Leukemia, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hematologic Neoplasms; Blast Crisis; Blastic Plasmacytoid Dendritic Cell Neoplasm; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Anemia; Microscopic Polyangiitis; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Granulomatosis with Polyangiitis; Candidiasis, Vulvovaginal; Lymphoma, B-Cell | Details |
Rituximab biosimilar (Pfizer) | PF-05280586; PF-5280586 | Approved | Pfizer Inc | Ruxience | United States | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Microscopic Polyangiitis; Granulomatosis with Polyangiitis | Pfizer Inc | 2019-07-23 | Lymphoma, Follicular; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Philadelphia Chromosome; Leukemia, B-Cell; Lymphoproliferative Disorders; Primary mediastinal B cell lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Richter's Syndrome; Blast Crisis; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Microscopic Polyangiitis; Leukemia, Lymphoid; Anemia; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Granulomatosis with Polyangiitis; Lymphoma, B-Cell, Marginal Zone | Details |
Obinutuzumab | RG-7159; RG-7195; RO-5072759; B-HH6-B-KV1-GE; R-7159; GA-101; RG7159-7 | Approved | Genentech Inc | Gazyva, Gazyvaro, Gazyva/Gazyvaro, 佳罗华 | United States | Leukemia, Lymphocytic, Chronic, B-Cell | Genentech Inc | 2013-11-01 | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Kidney Failure, Chronic; Central Nervous System Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Waldenstrom Macroglobulinemia; Lymphoma; Lymphoma, Non-Hodgkin; Nephrotic Syndrome; Lymphoproliferative Disorders; Lupus Erythematosus, Systemic; Lymphoma, Mantle-Cell; Lymphoma, B-Cell; Glomerulosclerosis, Focal Segmental; Lymphoma, Follicular; Lupus Nephritis; Glomerulonephritis, Membranous; Graft vs Host Disease; Lymphoma, Large B-Cell, Diffuse; Nephrosis; Leukemia, Lymphoid; Lymphoma, B-Cell, Marginal Zone; Leukemia | Details |
Rituximab biosimilar (Probiomed) | PBO-326 | Approved | Probiomed | Kikuzubam | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details | ||||
Ripertamab | SCT-400 | Approved | SinoCelltech Ltd | Mainland China | Lymphoma, Large B-Cell, Diffuse | SinoCelltech Ltd | 2022-08-23 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Central Nervous System Lymphoma | Details | |
Rituximab | IDEC-102; IDEC-C2B8; RO-452294; R-105; RG-105 | Approved | Biogen Inc | MabThera, MabThera/Rituxan, 美罗华, Ristova, Rituxan | United States | Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell | Genentech Inc, Idec Pharmaceuticals Corp | 1997-11-26 | Granulomatosis with Polyangiitis; Purpura, Thrombocytopenic, Idiopathic; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Polymyositis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Peripheral Nervous System Diseases; Rejection of renal transplantation; Non-radiographic axial spondyloarthritis; Liver Cirrhosis, Biliary; Myasthenia Gravis; Diabetes Mellitus, Type 1; HIV Infections; Leukemia; Opsoclonus-Myoclonus Syndrome; Ocular Motility Disorders; Keratoconjunctivitis Sicca; Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma, B-Cell, Marginal Zone; Multiple Sclerosis, Relapsing-Remitting; Scleritis; ST Elevation Myocardial Infarction; Microscopic Polyangiitis; Rejection of liver transplantation; Renal Insufficiency; Dermatomyositis; Nephrosis; Myositis; Schizophrenia; Hemophilia A; Immunoglobulin G4-Related Disease; Pulmonary Alveolar Proteinosis; Stomach Neoplasms; Graft vs Host Disease; Lymphoma, Large B-Cell, Diffuse; Scleroderma, Systemic; Arthritis, Rheumatoid; Kidney Diseases; P | Details |
Ocrelizumab | R-1594; RG-1594; PRO-70769; RO-4964913; rhuMab 2H7 | Approved | Genentech Inc | Ocrevus | United States | Multiple Sclerosis | Genentech Inc | 2017-03-28 | Multiple Sclerosis, Relapsing-Remitting; Schizophrenia; Arthritis, Rheumatoid; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Lupus Nephritis; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Encephalitis | Details |
rituximab biosimilar (Zenotech) | Approved | Zenotech Laboratories | India | Lymphoma, Non-Hodgkin | Zenotech Laboratories | 2013-02-01 | Lymphoma, Non-Hodgkin | Details | ||
Rituximab biosimilar (Intas Biopharmaceuticals) | Approved | Intas Biopharmaceuticals | Mabtas | India | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Intas Biopharmaceuticals | 2013-01-01 | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Mosunetuzumab | BTCT-4465A; RO-7030816; CD20-TBD; RG-7828 | Approved | Genentech Inc | Lunsumio | EU | Lymphoma, Follicular | Roche Registration Gmbh | 2022-06-03 | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lupus Erythematosus, Systemic; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Epcoritamab | GEN-3013; ABBV-GMAB-3013 | Approved | Genmab A/S, Abbvie Inc | Tepkinly, TEPKINLY, EPKINLY | United States | Lymphoma, Large B-Cell, Diffuse | Genmab Us Inc | 2023-05-19 | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Richter's Syndrome; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab biosimilar (Dr Reddy's Laboratories) | Approved | Dr.Reddy's Laboratories Ltd | Tidecron, Reditux | India | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Dr.Reddy's Laboratories Ltd | 2007-01-01 | Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details | |
Glofitamab | RG-6026; RO-7082859; RG6026-2 | Approved | F. Hoffmann-La Roche Ltd | COLUMVI, 高罗华 | Canada | Lymphoma, Large B-Cell, Diffuse | F. Hoffmann-La Roche Ltd | 2023-03-25 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma | Details |
Rituximab biosimilar (Celltrion) | CT-P10 | Approved | Celltrion Inc | Truxima, Blitzima, Ritemvia, Rituzena | EU | Leukemia, Lymphocytic, Chronic, B-Cell; Granulomatosis with Polyangiitis; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Microscopic Polyangiitis | Celltrion Healthcare Hungary Kft | 2017-02-17 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Philadelphia Chromosome; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Leukemia, Myelogenous, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Blast Crisis; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Anemia; Microscopic Polyangiitis; Leukemia, Lymphoid; Granulomatosis with Polyangiitis; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase | Details |
Hyaluronidase/Rituximab | Approved | Genentech Inc | Rituxan Hycela | United States | Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular | Genentech Inc | 2017-06-22 | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Ublituximab | TG-1101; TGTX-1101; LFB-R603; TG-1303; EMAB-6; R-603 | Approved | Tg Therapeutics Inc | Utuxin, BRIUMVI | United States | Multiple Sclerosis | Tg Therapeutics Inc | 2022-12-28 | Multiple Sclerosis, Relapsing-Remitting; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis; Lymphoma, Mantle-Cell; Neuromyelitis Optica; Lymphoma, Follicular; Richter's Syndrome; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma | Details |
Rituximab Biosimilar(Shanghai Institute Of Biological Products) | SIBP-02 | Approved | Shanghai Institute Of Biological Products Co Ltd | 生利健 | Mainland China | Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular | Shanghai Institute Of Biological Products Co Ltd | 2024-03-19 | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Ibritumomab tiuxetan | IDEC-In2B8; BAY86-5128; SHL-749; IDEC-Y2B8; IDEC-129; IDEC-2B8-MX-DTPA | Approved | Biogen Inc | Zevalin, Zavalin | United States | Lymphoma, B-Cell | Spectrum Pharmaceuticals Inc | 2002-02-19 | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Zuberitamab | HS-006 | Approved | Zhejiang Hisun Pharmaceutical Co Ltd | 安瑞昔 | Mainland China | Lymphoma, Large B-Cell, Diffuse | BioRay Pharmaceutical Co Ltd | 2023-05-12 | Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Thrombocytopenia | Details |
Ofatumumab | OMB-157; HuMax-CD2; GSK-1841157; 2F2 | Approved | Genmab A/S | Arzerra, Kesimpta | United States | Leukemia, Lymphocytic, Chronic, B-Cell | Novartis Pharma Ag | 2009-10-26 | Leukemia; Multiple Sclerosis, Relapsing-Remitting; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Multiple Sclerosis; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus | Details |
Rituximab biosimilar (Innovent Biologics) | IBI-301 | Approved | Innovent Biologics(Suzhou) Co Ltd | 达伯华, HALPRYZA | Mainland China | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Innovent Biologics(Suzhou) Co Ltd | 2020-09-30 | Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell; Burkitt Lymphoma; Leukemia, B-Cell; Philadelphia Chromosome; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, B-Cell; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blast Crisis; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Anemia; Hematologic Neoplasms; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic | Details |
Rituximab biosimilar (Sandoz) | GP-2013 | Approved | Sandoz | Riximyo, Rixathon | EU | Microscopic Polyangiitis; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell; Arthritis, Rheumatoid; Granulomatosis with Polyangiitis | Sandoz Gmbh | 2017-06-15 | Granulomatosis with Polyangiitis; Lymphoma, B-Cell; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab biosimilar (AryoGen Biopharma) | Approved | Aryogen Biopharma | Zytux | Iran | Leukemia, Myelogenous, Chronic; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Granulomatosis with Polyangiitis; Microscopic Polyangiitis | Aryogen Biopharma | 2014-01-01 | Leukemia, Myelogenous, Chronic; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details | |
Rituximab biosimilar (Biosidus) | Approved | Biosidus | Argentina | Hematologic Neoplasms | Biosidus | 2013-06-01 | Hematologic Neoplasms | Details | ||
Rituximab biosimilar (mAbxience) | RTXM-83; mAbx-02 | Approved | Mabxience Sa | Novex | Argentina | Lymphoma, Large B-Cell, Diffuse | Mabxience Sa | 2015-01-01 | Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Philadelphia Chromosome; Leukemia, Myelogenous, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Blast Crisis; Lymphoma, Large B-Cell, Diffuse; Anemia; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase | Details |
Rituximab biosimilar (Hetero Drugs) | Approved | Hetero Drugs Ltd | Maball, Mabura | India | Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Hetero Drugs Ltd | 2015-01-01 | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Rituximab biosimilar (Center of Molecular Immunology) | Approved | Center Of Molecular Immunology | CIMAbior, RituxCIM | Cuba | Lymphoma, Non-Hodgkin | null | 2017-04-01 | Lymphoma, Non-Hodgkin | Details | |
Rituximab biosimilar (Biocad) | BCD-020 | Approved | Biocad | Acellbia | Russian Federation | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin | Biocad | 2015-01-01 | Lymphoma, B-Cell, Marginal Zone; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab biosimilar (Reliance Life Sciences) | R-TPR-017 | Approved | Reliance Life Sciences | Toritz, RituxiRel | India | Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid | null | 2016-01-01 | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (CTTQ Pharma) | TQB-2303 | Approved | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Mainland China | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | 2023-05-26 | Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma, T-Cell | Details | ||
Rituximab biosimilar (Shanghai Henlius Biotech) | HLX-01 | Approved | Shanghai Henlius Biotech Inc | 汉利康 | Mainland China | Lymphoma, Non-Hodgkin | Shanghai Henlius Biopharmaceuticals Co Ltd | 2019-02-22 | Lymphoma, B-Cell; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (Amgen) | ABP-798; APB-798 | Approved | Amgen Inc | Riabni | United States | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin | Amgen Inc | 2020-12-17 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Philadelphia Chromosome; Lymphoproliferative Disorders; Leukemia, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hematologic Neoplasms; Blast Crisis; Blastic Plasmacytoid Dendritic Cell Neoplasm; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Anemia; Microscopic Polyangiitis; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Granulomatosis with Polyangiitis; Candidiasis, Vulvovaginal; Lymphoma, B-Cell | Details |
Rituximab biosimilar (Pfizer) | PF-05280586; PF-5280586 | Approved | Pfizer Inc | Ruxience | United States | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Microscopic Polyangiitis; Granulomatosis with Polyangiitis | Pfizer Inc | 2019-07-23 | Lymphoma, Follicular; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Philadelphia Chromosome; Leukemia, B-Cell; Lymphoproliferative Disorders; Primary mediastinal B cell lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Richter's Syndrome; Blast Crisis; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Microscopic Polyangiitis; Leukemia, Lymphoid; Anemia; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Granulomatosis with Polyangiitis; Lymphoma, B-Cell, Marginal Zone | Details |
Obinutuzumab | RG-7159; RG-7195; RO-5072759; B-HH6-B-KV1-GE; R-7159; GA-101; RG7159-7 | Approved | Genentech Inc | Gazyva, Gazyvaro, Gazyva/Gazyvaro, 佳罗华 | United States | Leukemia, Lymphocytic, Chronic, B-Cell | Genentech Inc | 2013-11-01 | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Kidney Failure, Chronic; Central Nervous System Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Waldenstrom Macroglobulinemia; Lymphoma; Lymphoma, Non-Hodgkin; Nephrotic Syndrome; Lymphoproliferative Disorders; Lupus Erythematosus, Systemic; Lymphoma, Mantle-Cell; Lymphoma, B-Cell; Glomerulosclerosis, Focal Segmental; Lymphoma, Follicular; Lupus Nephritis; Glomerulonephritis, Membranous; Graft vs Host Disease; Lymphoma, Large B-Cell, Diffuse; Nephrosis; Leukemia, Lymphoid; Lymphoma, B-Cell, Marginal Zone; Leukemia | Details |
Rituximab biosimilar (Probiomed) | PBO-326 | Approved | Probiomed | Kikuzubam | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details | ||||
Ripertamab | SCT-400 | Approved | SinoCelltech Ltd | Mainland China | Lymphoma, Large B-Cell, Diffuse | SinoCelltech Ltd | 2022-08-23 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Central Nervous System Lymphoma | Details | |
Rituximab | IDEC-102; IDEC-C2B8; RO-452294; R-105; RG-105 | Approved | Biogen Inc | MabThera, MabThera/Rituxan, 美罗华, Ristova, Rituxan | United States | Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell | Genentech Inc, Idec Pharmaceuticals Corp | 1997-11-26 | Granulomatosis with Polyangiitis; Purpura, Thrombocytopenic, Idiopathic; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Polymyositis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Peripheral Nervous System Diseases; Rejection of renal transplantation; Non-radiographic axial spondyloarthritis; Liver Cirrhosis, Biliary; Myasthenia Gravis; Diabetes Mellitus, Type 1; HIV Infections; Leukemia; Opsoclonus-Myoclonus Syndrome; Ocular Motility Disorders; Keratoconjunctivitis Sicca; Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma, B-Cell, Marginal Zone; Multiple Sclerosis, Relapsing-Remitting; Scleritis; ST Elevation Myocardial Infarction; Microscopic Polyangiitis; Rejection of liver transplantation; Renal Insufficiency; Dermatomyositis; Nephrosis; Myositis; Schizophrenia; Hemophilia A; Immunoglobulin G4-Related Disease; Pulmonary Alveolar Proteinosis; Stomach Neoplasms; Graft vs Host Disease; Lymphoma, Large B-Cell, Diffuse; Scleroderma, Systemic; Arthritis, Rheumatoid; Kidney Diseases; P | Details |
Ocrelizumab | R-1594; RG-1594; PRO-70769; RO-4964913; rhuMab 2H7 | Approved | Genentech Inc | Ocrevus | United States | Multiple Sclerosis | Genentech Inc | 2017-03-28 | Multiple Sclerosis, Relapsing-Remitting; Schizophrenia; Arthritis, Rheumatoid; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Lupus Nephritis; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Encephalitis | Details |
rituximab biosimilar (Zenotech) | Approved | Zenotech Laboratories | India | Lymphoma, Non-Hodgkin | Zenotech Laboratories | 2013-02-01 | Lymphoma, Non-Hodgkin | Details | ||
Rituximab biosimilar (Intas Biopharmaceuticals) | Approved | Intas Biopharmaceuticals | Mabtas | India | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Intas Biopharmaceuticals | 2013-01-01 | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Mosunetuzumab | BTCT-4465A; RO-7030816; CD20-TBD; RG-7828 | Approved | Genentech Inc | Lunsumio | EU | Lymphoma, Follicular | Roche Registration Gmbh | 2022-06-03 | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lupus Erythematosus, Systemic; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Epcoritamab | GEN-3013; ABBV-GMAB-3013 | Approved | Genmab A/S, Abbvie Inc | Tepkinly, TEPKINLY, EPKINLY | United States | Lymphoma, Large B-Cell, Diffuse | Genmab Us Inc | 2023-05-19 | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Richter's Syndrome; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab biosimilar (Dr Reddy's Laboratories) | Approved | Dr.Reddy's Laboratories Ltd | Tidecron, Reditux | India | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Dr.Reddy's Laboratories Ltd | 2007-01-01 | Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details | |
Glofitamab | RG-6026; RO-7082859; RG6026-2 | Approved | F. Hoffmann-La Roche Ltd | COLUMVI, 高罗华 | Canada | Lymphoma, Large B-Cell, Diffuse | F. Hoffmann-La Roche Ltd | 2023-03-25 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Rituximab biosimilar (Samsung) | SAIT-101 | Phase 3 Clinical | Samsung Biologics Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, T-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, B-Cell; Lymphoproliferative Disorders; Philadelphia Chromosome; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blast Crisis; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Arthritis, Rheumatoid; Anemia; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase | Details |
Rituximab biosimilar (Hualan Biological Engineering) | WBP-263 | Phase 3 Clinical | Hualan Genetic Engineering Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (Boehringer Ingelheim) | BI-695500 | Phase 3 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, B-Cell; Lymphoproliferative Disorders; Philadelphia Chromosome; Pancytopenia; Plasmablastic Lymphoma; Lymphoma, Mantle-Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blast Crisis; Leukemia, Myelomonocytic, Chronic; Arthritis, Rheumatoid; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Anemia; Candidiasis, Vulvovaginal; Hematologic Neoplasms; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Lymphoma, B-Cell, Marginal Zone | Details |
Recombinant humanized monoclonal antibody MIL62 | MIL62 | Phase 3 Clinical | Beijing Innocare Pharma Tech Co Ltd, Beijing Mabworks Biotech Co Ltd | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Nephrosis; Glomerulonephritis, Membranous; Lupus Nephritis; Lupus Erythematosus, Systemic; Lymphoma, Follicular; Neuromyelitis Optica; Lymphoma, Non-Hodgkin | Details |
Recombinant chimeric anti-CD20 antibody (Shanghai Institute of Biological Products) | Phase 3 Clinical | Shanghai Institute Of Biological Products Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details | |
Divozilimab | BCD-132 | Phase 3 Clinical | Biocad | Scleroderma, Systemic; Multiple Sclerosis; Neuromyelitis Optica | Details |
Ocrelizumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Multiple Sclerosis | Details | |
BAT-4406F | BAT-4406; BAT-4406F | Phase 3 Clinical | Bio-Thera Solutions Ltd | Neuromyelitis Optica | Details |
Rituximab biosimilar (Nanjing Yoko Biomedical) | GB-241 | Phase 3 Clinical | Genor Biopharma Co Ltd, Nanjing Yoko Biomedical Co Ltd | Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Philadelphia Chromosome; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, B-Cell; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blast Crisis; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Hematologic Neoplasms; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase | Details |
Rituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech) | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details | |
Ocrelizumab biosimilar (Celltrion) | CT-P53 | Phase 3 Clinical | Celltrion Inc | Multiple Sclerosis, Relapsing-Remitting | Details |
Iodine 131 tositumomab | TST/I131-TST | Phase 3 Clinical | Glaxosmithkline Plc | Lymphoma, B-Cell; Leukemia, Lymphoid; Hodgkin Disease; Multiple Myeloma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Crosslink Pharmaceutical) | B-007 | Phase 3 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd | Myasthenia Gravis; Lymphoma, B-Cell; Nephrosis; Glomerulonephritis, Membranous; Lymphoma, Non-Hodgkin; Pemphigus | Details |
Rituximab biosimilar(Shandong New Time Pharmaceutical) | H-02; F-007 | Phase 3 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details |
Imvotamab | IGM-2323 | Phase 2 Clinical | Igm Biosciences Inc | Lymphoma, B-Cell, Marginal Zone; Myositis; Lupus Erythematosus, Cutaneous; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lupus Erythematosus, Systemic; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Arthritis; Lymphoma, Non-Hodgkin | Details |
Anti-CD20 CART-transduced T cells (Cellular Biomedicine Group) | CART-20; CBM-C20.1; CBM-CD20 1 | Phase 2 Clinical | Pla General Hospital | Leukemia; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic | Details |
BVX20-CD20 antibody (Biocon/Vaccinex) | BVX-20; BVX20-MAb | Phase 2 Clinical | Biocon Ltd, Vaccinex Inc | Lymphoma, Non-Hodgkin | Details |
Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) | Phase 2 Clinical | Southwest Hospital Chongqing | Lymphoma, Large B-Cell, Diffuse | Details | |
Rituximab biosimilar (JHL Biotech) | JHL-1101 | Phase 2 Clinical | JHL Biotech | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma, Follicular; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell | Details |
Zamtocabtagene autoleucel | MB-CART2019.1 | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, Large B-Cell, Diffuse | Details |
IMM-0306 | IMC-002; IMM-0306 | Phase 2 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
Allogeneic anti-CD20 CAR-T cell therapy (Precision BioSciences) | PBCAR-20A | Phase 2 Clinical | Precision Biosciences Inc | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
ELC-301 | ELC301; ELC-301 | Phase 2 Clinical | Elicera Therapeutics AB, Uppsala University | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
MBS-303 | MBS-303 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
UCART-20x22 | UCART-20x22 | Phase 2 Clinical | Cellectis Sa | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
bbT-369 | bbT-369 | Phase 2 Clinical | Bluebird Bio Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
GB-261 | GB-261 | Phase 2 Clinical | Genor Biopharma Co Ltd | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CHO-H01 | CHO-H01 | Phase 2 Clinical | Academia Sinica | Neoplasms; Lymphoma, Non-Hodgkin | Details |
MB-CART19.1 (Miltenyi Biotec) | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma | Details |
MRG001 | MRG-001 | Phase 2 Clinical | Motor Neuron Disease; Lymphoma, B-Cell; Hepatitis, Alcoholic; Cytokine Release Syndrome; Respiratory Tract Diseases; Respiratory Distress Syndrome, Adult; Lymphoma, Non-Hodgkin; Respiratory Insufficiency; Amyotrophic Lateral Sclerosis | Details | |
IMPT-514 | IMPT-514 | Phase 2 Clinical | ImmPACT Bio USA Inc | Lupus Nephritis; Lupus Erythematosus, Systemic | Details |
IPH-6501 | IPH-6501; IPH-65 | Phase 2 Clinical | Innate Pharma SA | Neoplasms; Lymphoma, Non-Hodgkin | Details |
IMPT-314 | IMPT-314 | Phase 2 Clinical | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
CD20 monoclonal antibody(The First Affiliated Hospital of Soochow University) | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Anemia, Aplastic | Details | |
CD19/CD20 bispecific CAR-T cells (Shanghai Cellular) | Phase 2 Clinical | Shanghai Cellular Biopharmaceutical Group Ltd | Lymphoma, B-Cell | Details | |
ALETA-001 | ALETA-001 | Phase 2 Clinical | Aleta BioTherapeutics Inc | Lymphoma, B-Cell; Leukemia; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details |
Rituximab Biosimilar (Istituto Giannina Gaslini) | Phase 2 Clinical | Istituto Giannina Gaslini | Nephrotic Syndrome | Details | |
1-A-46 | BR-110; 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 | Phase 2 Clinical | Chengdu Chimagen Biosciences Co Ltd, BioRay Pharmaceutical Co Ltd | Lymphoma, B-Cell; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
ICP-B02 | CM-355; ICP-B02 | Phase 2 Clinical | Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd | Hematologic Neoplasms; Hematoma; Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Lymphoma, B-Cell | Details | |
Prizloncabtagene autoleucel | C-CAR039; C-CAR-039; C CAR 039; EXP-039 | Phase 2 Clinical | Cellular Biomedicine Group Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
EX-103 | EX-103; EX103 | Phase 2 Clinical | Guangzhou Excelmab Inc | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) | Phase 2 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma | Details | |
Anti-CD20 CAR T-cell therapy (Shanghai Longyao Biotechnology) | Phase 2 Clinical | Shanghai Longyao Biological Technology Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details | |
MB-106 | MB-106 | Phase 2 Clinical | Fred Hutchinson Cancer Research Center | Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) | Phase 2 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Pancreatic Neoplasms; Lymphoma, Non-Hodgkin | Details | |
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) | Phase 1 Clinical | Henan Provincial Cancer Hospital | Lymphoma, B-Cell | Details | |
Recombinant Fc-glycosylated anti-CD20 monoclonal antibody (Bio-Thera Solutions) | BAT-4306F | Phase 1 Clinical | Bio-Thera Solutions Ltd | Lymphoma, Non-Hodgkin | Details |
TRS-005 | TRS-005 | Phase 1 Clinical | Zhejiang Teruisi Pharmaceutical Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (International Biotech Center Generium) | GNR-006 | Phase 1 Clinical | International Biotech Center Generium | Lymphoma, B-Cell | Details |
Recombinant anti-CD20 chimeric monoclonal antibody (Livzon Group) | LZM-002 | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
MB-CART20.1 (Miltenyi Biotec) | Phase 1 Clinical | Miltenyi Biotec | Melanoma | Details | |
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) | Phase 1 Clinical | Fujian Medical University | Lymphoma, Large B-Cell, Diffuse | Details | |
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center, National Cancer Institute | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin | Details | |
Rituximab biosimilar (Shanghai CP Guojian Pharmaceutical) | CMAB-304; 304R | Phase 1 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Lymphoma, Large B-Cell, Diffuse; Multicentric Castleman's Disease (MCD); Burkitt Lymphoma; Sarcoma, Kaposi | Details | |
Anti-CD20 allogeneic CAR-T cell therapy (Nanjing Medical University) | LUCAR-20S | Phase 1 Clinical | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Bendamustine Hydrochloride/Rituximab | Phase 1 Clinical | 1globe Biomedical Co Ltd | Lymphoma, B-Cell | Details | |
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Pharma) | B001; B-001; B001A; B001-A; B001C; B001-C | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Multiple Sclerosis; Neuromyelitis Optica; Lymphoma, Non-Hodgkin; Lymphoma | Details |
Rituximab biosimilar (Gedeon Richter) | RGB-03 | Phase 1 Clinical | Gedeon Richter | Arthritis, Rheumatoid | Details |
CD20-directed CAR-T cell therapy (Tongji Hospital) | C-CAR066 | Phase 1 Clinical | Tongji Hospital, Cellular Biomedicine Group Inc, Shanghai Cellular Biopharmaceutical Group Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
JS-203 | JS-203 | Phase 1 Clinical | Shanghai Junshi Biological Engineering Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
Dual CD19/CD20 targeting CAR-T therapy(Poseida Therapeutics) | Phase 1 Clinical | Poseida Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD20 CAR-T cell therapy (Shanghai Longyao Biotechnology) | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
KITE-363 | KITE-363 | Phase 1 Clinical | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse | Details | |
ACE-1831 | ACE-1831 | Phase 1 Clinical | Acepodia Biotech Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) | Phase 1 Clinical | Uclas Jonsson Comprehensive Cancer Center | Candidiasis, Vulvovaginal; Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
LUCAR-G39P | LUCAR-G39P | Phase 1 Clinical | Lymphoma, Non-Hodgkin | Details | |
Allogenic Chimeric Antigen Receptor(CAR)-T Cell Therapy(Beijing Cancer Hospital) | LUCAR-20SP | Phase 1 Clinical | Beijing Cancer Hospital | Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (Mabscale) | Phase 1 Clinical | Mabscale LLC | Arthritis, Rheumatoid | Details | |
ASP-2802 | ASP2802; ASP-2802 | Phase 1 Clinical | Astellas Pharma Global Development Inc | Lymphoma, B-Cell | Details |
JNJ-1493 | JNJ-1493 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Lymphoma, B-Cell | Details |
C-CAR168 CAR T-cell therapy (AbelZeta) | C-CAR168 | Phase 1 Clinical | AbelZeta Pharma Inc | Multiple Sclerosis, Relapsing-Remitting; Autoimmune Diseases; Neuromyelitis Optica; Lupus Erythematosus, Systemic; Muscular Diseases | Details |
SCTB-35 | SCTB35; SCTB-35 | Phase 1 Clinical | SinoCelltech Ltd | Lymphoma, B-Cell | Details |
Recombinant human anti-CD20 momoclonal antibody(Shanghai Crosslink Pharma) | Phase 1 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd | Myasthenia Gravis; Pemphigus | Details | |
Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells(NIH) | Phase 1 Clinical | National Cancer Institute | Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
RO-7121932 | RO7121932; RO-7121932; RO 7121932; RG-6035 | Phase 1 Clinical | Genentech Inc | Multiple Sclerosis | Details |
TanCART19/20 | Phase 1 Clinical | Pla General Hospital | Neuromyelitis Optica | Details | |
LCAR-AIO | LCAR-AIO; VHH CAR-T | Phase 1 Clinical | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CAR-20-19-22 | CAR-20-19-22 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab biosimilar (Zhejiang Teruisi Pharmaceutical) | TRS001 | Phase 1 Clinical | Zhejiang Teruisi Pharmaceutical Inc | Lymphoma | Details |
QLP-31907 | QLP-31907; QLP31907; PSB-202 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
ADI-001 | ADI-001 | Phase 1 Clinical | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma | Details | |
TQB-2825 | TQB-2825 | Phase 1 Clinical | Wuxi Biologics Co Ltd | Hematologic Neoplasms | Details |
CD19/CD20 CAR-T Cell Therapy (PersonGen) | Phase 1 Clinical | Persongen Biotherapeutics | Details | ||
JMT-601 | JMT-601 | Phase 1 Clinical | Shanghai Jmt-Bio Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
LY007 | LY007 | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) | Phase 1 Clinical | First Affiliated Hospital Of Zhejiang University | Lymphoma, Large B-Cell, Diffuse | Details | |
Plamotamab | XmAb-13676 | Phase 1 Clinical | Xencor Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University, Shanghai YaKe Biotechnology Co Ltd | Hematologic Neoplasms | Details | |
Rituximab/Paclitaxel | AR-160 | Phase 1 Clinical | Mayo Clinic | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD20 CAR-T cell therapy (Wuhan Bio-Raid) | Clinical | Wuhan BioRaid Biotechnology Co Ltd | Neoplasms | Details | |
Rituximab biosimilar(Bioxpress) | BXT-2336 | Clinical | Bioxpress Therapeutics Sa | Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab/Bendamustine/Cytarabine | Fondazione Italiana Linfomi Onlus | Details | |||
Rituximab biosimilar (Samsung) | SAIT-101 | Phase 3 Clinical | Samsung Biologics Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, T-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, B-Cell; Lymphoproliferative Disorders; Philadelphia Chromosome; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blast Crisis; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Arthritis, Rheumatoid; Anemia; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase | Details |
Rituximab biosimilar (Hualan Biological Engineering) | WBP-263 | Phase 3 Clinical | Hualan Genetic Engineering Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (Boehringer Ingelheim) | BI-695500 | Phase 3 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, B-Cell; Lymphoproliferative Disorders; Philadelphia Chromosome; Pancytopenia; Plasmablastic Lymphoma; Lymphoma, Mantle-Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blast Crisis; Leukemia, Myelomonocytic, Chronic; Arthritis, Rheumatoid; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Anemia; Candidiasis, Vulvovaginal; Hematologic Neoplasms; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Lymphoma, B-Cell, Marginal Zone | Details |
Recombinant humanized monoclonal antibody MIL62 | MIL62 | Phase 3 Clinical | Beijing Innocare Pharma Tech Co Ltd, Beijing Mabworks Biotech Co Ltd | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Nephrosis; Glomerulonephritis, Membranous; Lupus Nephritis; Lupus Erythematosus, Systemic; Lymphoma, Follicular; Neuromyelitis Optica; Lymphoma, Non-Hodgkin | Details |
Recombinant chimeric anti-CD20 antibody (Shanghai Institute of Biological Products) | Phase 3 Clinical | Shanghai Institute Of Biological Products Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details | |
Divozilimab | BCD-132 | Phase 3 Clinical | Biocad | Scleroderma, Systemic; Multiple Sclerosis; Neuromyelitis Optica | Details |
Ocrelizumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Multiple Sclerosis | Details | |
BAT-4406F | BAT-4406; BAT-4406F | Phase 3 Clinical | Bio-Thera Solutions Ltd | Neuromyelitis Optica | Details |
Rituximab biosimilar (Nanjing Yoko Biomedical) | GB-241 | Phase 3 Clinical | Genor Biopharma Co Ltd, Nanjing Yoko Biomedical Co Ltd | Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Philadelphia Chromosome; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, B-Cell; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blast Crisis; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Hematologic Neoplasms; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase | Details |
Rituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech) | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details | |
Ocrelizumab biosimilar (Celltrion) | CT-P53 | Phase 3 Clinical | Celltrion Inc | Multiple Sclerosis, Relapsing-Remitting | Details |
Iodine 131 tositumomab | TST/I131-TST | Phase 3 Clinical | Glaxosmithkline Plc | Lymphoma, B-Cell; Leukemia, Lymphoid; Hodgkin Disease; Multiple Myeloma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Crosslink Pharmaceutical) | B-007 | Phase 3 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd | Myasthenia Gravis; Lymphoma, B-Cell; Nephrosis; Glomerulonephritis, Membranous; Lymphoma, Non-Hodgkin; Pemphigus | Details |
Rituximab biosimilar(Shandong New Time Pharmaceutical) | H-02; F-007 | Phase 3 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details |
Imvotamab | IGM-2323 | Phase 2 Clinical | Igm Biosciences Inc | Lymphoma, B-Cell, Marginal Zone; Myositis; Lupus Erythematosus, Cutaneous; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lupus Erythematosus, Systemic; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Arthritis; Lymphoma, Non-Hodgkin | Details |
Anti-CD20 CART-transduced T cells (Cellular Biomedicine Group) | CART-20; CBM-C20.1; CBM-CD20 1 | Phase 2 Clinical | Pla General Hospital | Leukemia; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic | Details |
BVX20-CD20 antibody (Biocon/Vaccinex) | BVX-20; BVX20-MAb | Phase 2 Clinical | Biocon Ltd, Vaccinex Inc | Lymphoma, Non-Hodgkin | Details |
Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) | Phase 2 Clinical | Southwest Hospital Chongqing | Lymphoma, Large B-Cell, Diffuse | Details | |
Rituximab biosimilar (JHL Biotech) | JHL-1101 | Phase 2 Clinical | JHL Biotech | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma, Follicular; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell | Details |
Zamtocabtagene autoleucel | MB-CART2019.1 | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, Large B-Cell, Diffuse | Details |
IMM-0306 | IMC-002; IMM-0306 | Phase 2 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
Allogeneic anti-CD20 CAR-T cell therapy (Precision BioSciences) | PBCAR-20A | Phase 2 Clinical | Precision Biosciences Inc | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
ELC-301 | ELC301; ELC-301 | Phase 2 Clinical | Elicera Therapeutics AB, Uppsala University | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
MBS-303 | MBS-303 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
UCART-20x22 | UCART-20x22 | Phase 2 Clinical | Cellectis Sa | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
bbT-369 | bbT-369 | Phase 2 Clinical | Bluebird Bio Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
GB-261 | GB-261 | Phase 2 Clinical | Genor Biopharma Co Ltd | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CHO-H01 | CHO-H01 | Phase 2 Clinical | Academia Sinica | Neoplasms; Lymphoma, Non-Hodgkin | Details |
MB-CART19.1 (Miltenyi Biotec) | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma | Details |
MRG001 | MRG-001 | Phase 2 Clinical | Motor Neuron Disease; Lymphoma, B-Cell; Hepatitis, Alcoholic; Cytokine Release Syndrome; Respiratory Tract Diseases; Respiratory Distress Syndrome, Adult; Lymphoma, Non-Hodgkin; Respiratory Insufficiency; Amyotrophic Lateral Sclerosis | Details | |
IMPT-514 | IMPT-514 | Phase 2 Clinical | ImmPACT Bio USA Inc | Lupus Nephritis; Lupus Erythematosus, Systemic | Details |
IPH-6501 | IPH-6501; IPH-65 | Phase 2 Clinical | Innate Pharma SA | Neoplasms; Lymphoma, Non-Hodgkin | Details |
IMPT-314 | IMPT-314 | Phase 2 Clinical | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
CD20 monoclonal antibody(The First Affiliated Hospital of Soochow University) | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Anemia, Aplastic | Details | |
CD19/CD20 bispecific CAR-T cells (Shanghai Cellular) | Phase 2 Clinical | Shanghai Cellular Biopharmaceutical Group Ltd | Lymphoma, B-Cell | Details | |
ALETA-001 | ALETA-001 | Phase 2 Clinical | Aleta BioTherapeutics Inc | Lymphoma, B-Cell; Leukemia; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details |
Rituximab Biosimilar (Istituto Giannina Gaslini) | Phase 2 Clinical | Istituto Giannina Gaslini | Nephrotic Syndrome | Details | |
1-A-46 | BR-110; 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 | Phase 2 Clinical | Chengdu Chimagen Biosciences Co Ltd, BioRay Pharmaceutical Co Ltd | Lymphoma, B-Cell; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
ICP-B02 | CM-355; ICP-B02 | Phase 2 Clinical | Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd | Hematologic Neoplasms; Hematoma; Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Lymphoma, B-Cell | Details | |
Prizloncabtagene autoleucel | C-CAR039; C-CAR-039; C CAR 039; EXP-039 | Phase 2 Clinical | Cellular Biomedicine Group Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
EX-103 | EX-103; EX103 | Phase 2 Clinical | Guangzhou Excelmab Inc | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) | Phase 2 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma | Details | |
Anti-CD20 CAR T-cell therapy (Shanghai Longyao Biotechnology) | Phase 2 Clinical | Shanghai Longyao Biological Technology Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details | |
MB-106 | MB-106 | Phase 2 Clinical | Fred Hutchinson Cancer Research Center | Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) | Phase 2 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Pancreatic Neoplasms; Lymphoma, Non-Hodgkin | Details | |
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) | Phase 1 Clinical | Henan Provincial Cancer Hospital | Lymphoma, B-Cell | Details | |
Recombinant Fc-glycosylated anti-CD20 monoclonal antibody (Bio-Thera Solutions) | BAT-4306F | Phase 1 Clinical | Bio-Thera Solutions Ltd | Lymphoma, Non-Hodgkin | Details |
TRS-005 | TRS-005 | Phase 1 Clinical | Zhejiang Teruisi Pharmaceutical Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (International Biotech Center Generium) | GNR-006 | Phase 1 Clinical | International Biotech Center Generium | Lymphoma, B-Cell | Details |
Recombinant anti-CD20 chimeric monoclonal antibody (Livzon Group) | LZM-002 | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
MB-CART20.1 (Miltenyi Biotec) | Phase 1 Clinical | Miltenyi Biotec | Melanoma | Details | |
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) | Phase 1 Clinical | Fujian Medical University | Lymphoma, Large B-Cell, Diffuse | Details | |
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center, National Cancer Institute | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin | Details | |
Rituximab biosimilar (Shanghai CP Guojian Pharmaceutical) | CMAB-304; 304R | Phase 1 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Lymphoma, Large B-Cell, Diffuse; Multicentric Castleman's Disease (MCD); Burkitt Lymphoma; Sarcoma, Kaposi | Details | |
Anti-CD20 allogeneic CAR-T cell therapy (Nanjing Medical University) | LUCAR-20S | Phase 1 Clinical | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Bendamustine Hydrochloride/Rituximab | Phase 1 Clinical | 1globe Biomedical Co Ltd | Lymphoma, B-Cell | Details | |
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Pharma) | B001; B-001; B001A; B001-A; B001C; B001-C | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Multiple Sclerosis; Neuromyelitis Optica; Lymphoma, Non-Hodgkin; Lymphoma | Details |
Rituximab biosimilar (Gedeon Richter) | RGB-03 | Phase 1 Clinical | Gedeon Richter | Arthritis, Rheumatoid | Details |
CD20-directed CAR-T cell therapy (Tongji Hospital) | C-CAR066 | Phase 1 Clinical | Tongji Hospital, Cellular Biomedicine Group Inc, Shanghai Cellular Biopharmaceutical Group Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
JS-203 | JS-203 | Phase 1 Clinical | Shanghai Junshi Biological Engineering Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
Dual CD19/CD20 targeting CAR-T therapy(Poseida Therapeutics) | Phase 1 Clinical | Poseida Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD20 CAR-T cell therapy (Shanghai Longyao Biotechnology) | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
KITE-363 | KITE-363 | Phase 1 Clinical | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse | Details | |
ACE-1831 | ACE-1831 | Phase 1 Clinical | Acepodia Biotech Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) | Phase 1 Clinical | Uclas Jonsson Comprehensive Cancer Center | Candidiasis, Vulvovaginal; Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
LUCAR-G39P | LUCAR-G39P | Phase 1 Clinical | Lymphoma, Non-Hodgkin | Details | |
Allogenic Chimeric Antigen Receptor(CAR)-T Cell Therapy(Beijing Cancer Hospital) | LUCAR-20SP | Phase 1 Clinical | Beijing Cancer Hospital | Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (Mabscale) | Phase 1 Clinical | Mabscale LLC | Arthritis, Rheumatoid | Details | |
ASP-2802 | ASP2802; ASP-2802 | Phase 1 Clinical | Astellas Pharma Global Development Inc | Lymphoma, B-Cell | Details |
JNJ-1493 | JNJ-1493 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Lymphoma, B-Cell | Details |
C-CAR168 CAR T-cell therapy (AbelZeta) | C-CAR168 | Phase 1 Clinical | AbelZeta Pharma Inc | Multiple Sclerosis, Relapsing-Remitting; Autoimmune Diseases; Neuromyelitis Optica; Lupus Erythematosus, Systemic; Muscular Diseases | Details |
SCTB-35 | SCTB35; SCTB-35 | Phase 1 Clinical | SinoCelltech Ltd | Lymphoma, B-Cell | Details |
Recombinant human anti-CD20 momoclonal antibody(Shanghai Crosslink Pharma) | Phase 1 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd | Myasthenia Gravis; Pemphigus | Details | |
Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells(NIH) | Phase 1 Clinical | National Cancer Institute | Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
RO-7121932 | RO7121932; RO-7121932; RO 7121932; RG-6035 | Phase 1 Clinical | Genentech Inc | Multiple Sclerosis | Details |
TanCART19/20 | Phase 1 Clinical | Pla General Hospital | Neuromyelitis Optica | Details | |
LCAR-AIO | LCAR-AIO; VHH CAR-T | Phase 1 Clinical | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CAR-20-19-22 | CAR-20-19-22 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab biosimilar (Zhejiang Teruisi Pharmaceutical) | TRS001 | Phase 1 Clinical | Zhejiang Teruisi Pharmaceutical Inc | Lymphoma | Details |
QLP-31907 | QLP-31907; QLP31907; PSB-202 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
ADI-001 | ADI-001 | Phase 1 Clinical | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma | Details | |
TQB-2825 | TQB-2825 | Phase 1 Clinical | Wuxi Biologics Co Ltd | Hematologic Neoplasms | Details |
CD19/CD20 CAR-T Cell Therapy (PersonGen) | Phase 1 Clinical | Persongen Biotherapeutics | Details | ||
JMT-601 | JMT-601 | Phase 1 Clinical | Shanghai Jmt-Bio Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
LY007 | LY007 | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) | Phase 1 Clinical | First Affiliated Hospital Of Zhejiang University | Lymphoma, Large B-Cell, Diffuse | Details | |
Plamotamab | XmAb-13676 | Phase 1 Clinical | Xencor Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University, Shanghai YaKe Biotechnology Co Ltd | Hematologic Neoplasms | Details | |
Rituximab/Paclitaxel | AR-160 | Phase 1 Clinical | Mayo Clinic | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD20 CAR-T cell therapy (Wuhan Bio-Raid) | Clinical | Wuhan BioRaid Biotechnology Co Ltd | Neoplasms | Details | |
Rituximab biosimilar(Bioxpress) | BXT-2336 | Clinical | Bioxpress Therapeutics Sa | Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab/Bendamustine/Cytarabine | Fondazione Italiana Linfomi Onlus | Details |
This web search service is supported by Google Inc.